                         SEQUENCE LISTING

<110>  Purdue Research Foundation
 
<120>  ENGINEERED NATURAL KILLER CELLS REDIRECTED TOWARD PURINERGIC 
       SIGNALING, CONSTRUCTS THEREOF, AND METHODS FOR USING THE SAME

<130>  68613-02

<150>  62/838,742
<151>  2019-04-25

<160>  9     

<170>  PatentIn version 3.5

<210>  1
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  signal peptide

<400>  1

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 
1               5                   10                  15      


Gly Ser Thr Gly 
            20  


<210>  2
<211>  242
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  an engineered antigen binding domain specific for CD73 and 
       including a scFv

<400>  2

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Tyr Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Ala Ile Ser Gly Ser Gly Gly Arg Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Leu Gly Tyr Gly Arg Val Asp Glu Trp Gly Arg Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 
        115                 120                 125             


Gly Gly Gly Ser Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly 
    130                 135                 140                 


Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Leu Ser Asn 
145                 150                 155                 160 


Ile Gly Arg Asn Pro Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala 
                165                 170                 175     


Pro Lys Leu Leu Ile Tyr Leu Asp Asn Leu Arg Leu Ser Gly Val Pro 
            180                 185                 190         


Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile 
        195                 200                 205             


Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp 
    210                 215                 220                 


Asp Asp Ser His Pro Gly Trp Thr Phe Gly Gly Gly Thr Lys Leu Thr 
225                 230                 235                 240 


Val Leu 
        


<210>  3
<211>  65
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  human FCyRIIIa stimulatory domain of a natural killer cell having
       a truncated extracellular domain

<400>  3

Ile Thr Gln Gly Leu Ala Val Ser Thr Ile Ser Ser Phe Phe Pro Pro 
1               5                   10                  15      


Gly Tyr Gln Val Ser Phe Cys Leu Val Met Val Leu Leu Phe Ala Val 
            20                  25                  30          


Asp Thr Gly Leu Tyr Phe Ser Val Lys Thr Asn Ile Arg Ser Ser Thr 
        35                  40                  45              


Arg Asp Trp Lys Asp His Lys Phe Lys Trp Arg Lys Asp Pro Gln Asp 
    50                  55                  60                  


Lys 
65  


<210>  4
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  a protease-sensitive linker

<400>  4

Leu Ser Gly Arg Ser Asp Asn His 
1               5               


<210>  5
<211>  28
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  a protease-sensitive linker flanked by a (Gly-Ser)3 linker and a 
       short Gly-Ser spacer

<400>  5

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Leu 
1               5                   10                  15      


Ser Gly Arg Ser Asp Asn His Gly Ser Ser Gly Thr 
            20                  25              


<210>  6
<211>  60
<212>  DNA
<213>  Homo sapiens

<400>  6
atggaaccct ggcccctgct gctgctgttt agcctgtgct ctgctggact ggtgctgggc       60


<210>  7
<211>  726
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  an engineered antigen binding domain specific for CD73 and 
       including a scFv

<400>  7
gaggtgcagc tgctggaatc tggcgggggc ctggtgcagc caggaggctc cctgaggctg       60

tcttgcgcag caagcggctt cacctttagc tcctacgcct attcctgggt gagacaggca      120

cctggcaagg gcctggagtg ggtgtctgcc atctccggct ctggcggcag gacatactat      180

gccgacagcg tgaagggccg gttcaccatc tccagagata actctaagaa tacactgtac      240

ctgcagatga actccctgag ggcagaggac accgccgtgt actattgcgc aaggctggga      300

tatggaaggg tggatgagtg gggaaggggc accctggtga cagtgtctag cggaggagga      360

ggatctggag gaggaggaag cggcggagga ggcagccagt ccgtgctgac acagccacct      420

tctgccagcg gaacccctgg acagagggtg acaatctcct gttctggcag cctgtccaac      480

atcggccgca acccagtgaa ttggtaccag cagctgccag gaaccgcacc aaagctgctg      540

atctatctgg acaatctgcg gctgagcggc gtgcccgata gattttctgg cagcaagtcc      600

ggcacatctg ccagcctggc aatcagcggc ctgcagtccg aggacgaggc agattactat      660

tgtgccacct gggatgactc tcaccctggc tggactttcg ggggaggaac taaactgacc      720

gtgctg                                                                 726


<210>  8
<211>  195
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  human FCyRIIIa stimulatory domain of a natural killer cell having
       a truncated extracellular domain

<400>  8
attacccagg gcctggcggt gagcaccatt agcagctttt ttccgccggg ctatcaggtg       60

agcttttgcc tggtgatggt gctgctgttt gcggtggata ccggcctgta ttttagcgtg      120

aaaaccaaca ttcgcagcag cacccgcgat tggaaagatc ataaatttaa atggcgcaaa      180

gatccgcagg ataaa                                                       195


<210>  9
<211>  990
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  an artificial construct having CD73 scFv fused with human 
       FcyRIIIa having a truncated extracellular domain

<400>  9
aagcttgcca ccatgtggca gctgctgctg cctaccgctc tgctgctgct ggtctccgcc       60

gaagtccagc tgctggaaag tggggggggc ctggtccagc caggaggcag cctgaggctg      120

tcctgcgcag catctggctt cacctttagc tcctacgcct attcttgggt gagacaggca      180

ccaggcaagg gcctggagtg ggtgagcgcc atcagcggat ccggaggcag gacatactat      240

gccgactccg tgaagggccg gtttaccatc agcagagata actccaagaa tacactgtac      300

ctgcagatga actccctgag ggcagaggac accgccgtgt actattgcgc aaggctggga      360

tatggaaggg tggatgagtg gggaaggggc accctggtga cagtgtctag cggaggagga      420

ggatccggag gaggaggatc tggcggcggc ggctctcaga gcgtgctgac ccagccacct      480

tccgcctctg gaaccccagg ccagagggtg acaatcagct gttccggctc tctgagcaac      540

atcggccgca accctgtgaa ttggtaccag cagctgcctg gcaccgcccc aaagctgctg      600

atctatctgg acaatctgcg gctgtctggc gtgcctgata gattttccgg ctctaagagc      660

ggcacatccg cctctctggc catctctggc ctgcagagcg aggacgaggc cgattactat      720

tgcgcaacct gggacgatag ccacccagga tggacattcg gcggaggaac caagctgaca      780

gtgctgatca cccagggcct ggccgtgagc acaatctcct ctttctttcc acccggctac      840

caggtgtcct tctgtctggt catggtgctg ctgtttgccg tggacaccgg cctgtatttc      900

agcgtgaaga caaatatcag atcatcaaca agagattgga aagaccataa gttcaagtgg      960

cggaaggacc cccaggacaa gtgactcgag                                       990


